Reproductive BioMedicine Online
Volume 19, Issue 6 , Pages 879-887 , December 2009

Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study

  • R Matorras

      Affiliations

    • Department of Obstetrics and Gynecology, Hospital de Cruces, País Vasco University, Baracaldo, Vizcaya, Spain
    • IVI Bilbao, Bilbao, Spain
    • Corresponding Author InformationCorrespondence:
    • ,
  • B Prieto

      Affiliations

    • Department of Obstetrics and Gynecology, Hospital de Cruces, País Vasco University, Baracaldo, Vizcaya, Spain
    • ,
  • A Exposito

      Affiliations

    • Department of Obstetrics and Gynecology, Hospital de Cruces, País Vasco University, Baracaldo, Vizcaya, Spain
    • ,
  • R Mendoza

      Affiliations

    • Department of Obstetrics and Gynecology, Hospital de Cruces, País Vasco University, Baracaldo, Vizcaya, Spain
    • ,
  • L Crisol

      Affiliations

    • Department of Obstetrics and Gynecology, Hospital de Cruces, País Vasco University, Baracaldo, Vizcaya, Spain
    • ,
  • P Herranz

      Affiliations

    • Merck Farma y Química, SL, Madrid, Spain
    • ,
  • S Burgués

      Affiliations

    • Merck Farma y Química, SL, Madrid, Spain

Received 10 February 2009 ,Revised 17 March 2009 ,Accepted 6 July 2009.

References 

  1. Alviggi C, Clarizia R, Mollo A, et al. Who needs LH in ovarian stimulation?. Reproductive BioMedicine Online. 2006;12:599–607
  2. Barrenetxea G, Agirregoikoa JA, Jiménez MR, et al. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in-vitro fertilization cycles. Fertility and Sterility. 2008;89:546–553
  3. Blitek A, Ziecik AJ. Effect of LH on prostaglandin F2alpha and prostaglandin E2 secretion by cultured porcine endometrial cells. Reproduction. 2005;130:105–112
  4. Bosch E, Labarta E, Simón C, et al. The impact of luteinizing hormone supplementation in gonadotropin releasing hormone antagonist cycles. An age adjusted randomized trial. Fertility and Sterility. 2008;90(suppl. 1):S41
  5. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reproduction. 2004;19:1979–1984
  6. Couzinet B, Lestrat N, Brailly S. Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. Journal of Clinical Endocrinology and Metabolism. 1988;66:552–556
  7. De Placido G, Mollo A, Clarizia R, et al. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertility and Sterility. 2006;85:247–250
  8. Durnerin CI, Erb K, Fleming R, et al. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Human Reproduction. 2008;23:421–426
  9. Esposito MA, Barnhart KT, Coutifaris C, Patrizio P. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertility and Sterility. 2001;75:519–524
  10. European Recombinant Human LH Study Group . Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose finding study. Journal of Clinical Endocrinology and Metabolism. 1998;83:1507–1514
  11. Fábregues F, Creus M, Peñarrubia J, et al. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertility and Sterility. 2006;85:925–931
  12. Griesinger G, Schultze-Mosgau A, Dafopoulos K, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Human Reproduction. 2005;20:1200–1206
  13. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reproductive BioMedicine Online. 2004;8:635–643
  14. Humaidan P, Bungum M, Bungum L, Andersen C. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Human Reproduction. 2002;17:2016–2021
  15. Kolibianakis EM, Kalogeropoulou L, Griesinger G, et al. Among patients treated with FSH and GnRH analogues for in-vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Human Reproduction Update. 2007;13:445–452
  16. Lisi F, Rinaldi L, Fishel S, et al. Use of recombinant LH in a group of unselected IVF patients. Reproductive BioMedicine Online. 2002;5:104–108
  17. Marrs R, Meldrum D, Muasher S, et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive BioMedicine Online. 2004;8:175–182
  18. Matorras R, Mendoza R, Expósito A, Rodríguez-Escudero FJ. Influence of the time interval between embryo catheter loading and discharging on the success of IVF. Human Reproduction. 2004;19:2027–2030
  19. Matorras R, Urquijo E, Mendoza R, et al. Ultrasound-guided embryo transfer improves pregnancy rates and increases the frequency of easy transfers. Human Reproduction. 2002;17:1762–1766
  20. Mishra S, Lei ZM, Rao ChV. A novel role of luteinizing hormone in the embryo development in cocultures. Biological Reproduction. 2003;68:1455–1462
  21. Mochtar MH, Vander Veen, Ziech M, vanWely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews. 2007;CD005070
  22. Nyboeandersen A, Humaidan P, Fried G, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in-vitro fertilization. A multicentre, prospective, randomized, controlled trial. Human Reproduction. 2008;23:427–434
  23. Reshef E, Lei ZM, Rao CV, et al. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. Journal of Clinical Endocrinology and Metabolism. 1990;70:421–430
  24. Shemesh M. Actions of gonadotrophins on the uterus. Reproduction. 2001;121:835–842
  25. Tarlatzis B, Tavmergen E, Szamatowicz M, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Human Reproduction. 2006;21:90–94
  26. Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Human Reproduction. 2002;17:3129–3137
  27. Veeck LL. Oocyte assessment and biological performance. Annals of the New York Academy of Science. 1988;541:259–274
  28. Weghofer A, Munné S, Brannath W, et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Human Reproduction. 2008;23:499–503
  29. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Human Reproduction. 2000;15:1003–1008

 Roberto Matorras, MD, PhD is Chairman of Obstetrics and Gynecology of the Basque Country University, Head of the Human Reproductive Unit of the Cruces Hospital (Vizcaya, Spain), and Scientific Director of the Clinic IVI-Bilbao, Spain. He is author of 400 scientific articles, 80 of them in peer-reviewed journals. He is a past President of the Spanish Society of Infertility. His main interest areas are IVF, endometriosis, and intrauterine insemination. Dr Roberto Matorras

PII: S1472-6483(09)00080-7

doi: 10.1016/j.rbmo.2009.09.016

Reproductive BioMedicine Online
Volume 19, Issue 6 , Pages 879-887 , December 2009

Article Tools

* Image Usage & Resolution